PvP Biologics

PvP Biologics is a California-based biotechnology company with a focus on creating therapies for those with celiac disease, a disorder which inflames an individual's small intestine when gluten in consumed. Its therapeutic product consists of an oral enzyme to alleviate symptoms of the disease, such as pain and internal damage.

The company's product is called TAK-062 (also known as Kuma062) and is a recombinant enzyme that is active under acidic stomach conditions. It was computationally engineered and enzymatically digests gluten in order to reduce the immune-reactive parts of gluten. This digestion occurs before gluten exits the stomach so that the small intestine is less likely to become inflamed, causing the pain and discomfort in celiac patients.

The product completed its Phase 1 clinical trial in early 2020 and is slated to move on to Phase 2 trials. In the Phase 2 trials, efficacy and dose ranges are set to be explored in patients with the disease who also manage a gluten-free diet.